Postoperative radiotherapy improves long-term survival in HER2-positive metastatic breast cancer: real-world evidence from the latest SEER database.

IF 3 3区医学 Q2 ONCOLOGY

Breast Cancer Research and Treatment Pub Date : 2025-03-14 DOI:10.1007/s10549-025-07665-y

Ling-Xiao Xie, Yang Liu, Yao-Guo Yang, Jing-Nan Wang, Yan-Qun Zhang, Tao Wang, Lu-Yang Bian, Hao Jiang, Xiao-Ming Su, Yong-Chun Zhou

{"title":"Postoperative radiotherapy improves long-term survival in HER2-positive metastatic breast cancer: real-world evidence from the latest SEER database.","authors":"Ling-Xiao Xie, Yang Liu, Yao-Guo Yang, Jing-Nan Wang, Yan-Qun Zhang, Tao Wang, Lu-Yang Bian, Hao Jiang, Xiao-Ming Su, Yong-Chun Zhou","doi":"10.1007/s10549-025-07665-y","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the role of Postoperative Radiotherapy (PORT) in HER2-positive metastatic breast cancer (MBC) in the context of targeted therapy and clarify the subgroups that may benefit from PORT.Methods: Clinical data of female patients with HER2-positive MBC from the surveillance, epidemiology, and end results (SEER) database for the years 2016-2020 were collected according to established inclusion and exclusion criteria. The impact of PORT on patient survival was assessed, and subgroup analyses were performed to identify populations with potential benefits from PORT.Results: A total of 541 patients from the SEER database were included in the analysis. The 3-year overall survival (OS) of the PORT group was significantly higher than that of the non-PORT group. (86.7% vs. 80.2%, P = 0.011). Multivariate analysis revealed that race and PORT were independent prognostic factors. Black patients and those who received PORT had longer overall survival (OS) (P < 0.05). Subgroup analysis suggested that PORT further improved OS in patients with mastectomy, advanced TN stage, high tumor grade, positive hormone receptor status, and multiple metastatic organs (P < 0.05).Conclusion: PORT further improves the survival of HER2-positive MBC. Subgroup analysis suggests that patients with locally advanced stage (T3-4, N2-3), Grade III, HR-positive status, bone-and-visceral metastasis, and those who have undergone mastectomy benefit significantly.","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-025-07665-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the role of Postoperative Radiotherapy (PORT) in HER2-positive metastatic breast cancer (MBC) in the context of targeted therapy and clarify the subgroups that may benefit from PORT.

Methods: Clinical data of female patients with HER2-positive MBC from the surveillance, epidemiology, and end results (SEER) database for the years 2016-2020 were collected according to established inclusion and exclusion criteria. The impact of PORT on patient survival was assessed, and subgroup analyses were performed to identify populations with potential benefits from PORT.

Results: A total of 541 patients from the SEER database were included in the analysis. The 3-year overall survival (OS) of the PORT group was significantly higher than that of the non-PORT group. (86.7% vs. 80.2%, P = 0.011). Multivariate analysis revealed that race and PORT were independent prognostic factors. Black patients and those who received PORT had longer overall survival (OS) (P < 0.05). Subgroup analysis suggested that PORT further improved OS in patients with mastectomy, advanced TN stage, high tumor grade, positive hormone receptor status, and multiple metastatic organs (P < 0.05).

Conclusion: PORT further improves the survival of HER2-positive MBC. Subgroup analysis suggests that patients with locally advanced stage (T3-4, N2-3), Grade III, HR-positive status, bone-and-visceral metastasis, and those who have undergone mastectomy benefit significantly.

查看原文本刊更多论文

术后放疗可提高 HER2 阳性转移性乳腺癌患者的长期生存率：来自最新 SEER 数据库的实际证据。

目的：评估靶向治疗背景下术后放疗（PORT）在HER2阳性转移性乳腺癌（MBC）中的作用，并明确可能从PORT中获益的亚组：根据既定的纳入和排除标准，从监测、流行病学和最终结果（SEER）数据库中收集了2016-2020年HER2阳性MBC女性患者的临床数据。评估了PORT对患者生存的影响，并进行了亚组分析，以确定可能从PORT中获益的人群：共有541名来自SEER数据库的患者被纳入分析。PORT组的3年总生存率（OS）明显高于非PORT组。(86.7%对80.2%，P=0.011）。多变量分析显示，种族和PORT是独立的预后因素。黑人患者和接受PORT治疗的患者总生存期（OS）更长（P 结论：PORT治疗进一步提高了乳腺癌患者的生存率：PORT 可进一步提高 HER2 阳性 MBC 的生存率。亚组分析表明，局部晚期（T3-4，N2-3）、III级、HR阳性、骨和内脏转移以及接受过乳房切除术的患者明显受益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Research and Treatment 医学-肿瘤学

CiteScore

6.80

自引率

2.60%

发文量

342

审稿时长

1 months

期刊介绍： Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.